Opioid-induced constipation: advances and clinical guidance

Alfred D. Nelson, Michael Camilleri

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Currently opioids are the most frequently used medications for chronic noncancer pain. Opioid-induced constipation is the most common adverse effect associated with prolonged use of opioids, having a major impact on quality of life. There is an increasing need to treat opioid-induced constipation. With the recent approval of medications for the treatment of opioid-induced constipation, there are several therapeutic approaches. This review addresses the clinical presentation and diagnosis of opioid-induced constipation, barriers to its diagnosis, effects of opioids in the gastrointestinal tract, differential tolerance to opiates in different gastrointestinal organs, medications approved and in development for the treatment of opioid-induced constipation, and a proposed clinical management algorithm for treating opioid-induced constipation in patients with noncancer pain.

Original languageEnglish (US)
Pages (from-to)121-134
Number of pages14
JournalTherapeutic Advances in Chronic Disease
Volume7
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Constipation
Opioid Analgesics
Opiate Alkaloids
Chronic Pain
Gastrointestinal Tract
Therapeutics
Quality of Life
Pain

Keywords

  • lubiprostone
  • methylnaltrexone
  • naloxegol
  • noncancer pain
  • peripheral µ opioid receptor antagonist
  • tolerance

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Opioid-induced constipation : advances and clinical guidance. / Nelson, Alfred D.; Camilleri, Michael.

In: Therapeutic Advances in Chronic Disease, Vol. 7, No. 2, 01.03.2016, p. 121-134.

Research output: Contribution to journalArticle

@article{53bae9c09a6f4468ad68174c1bdadaa6,
title = "Opioid-induced constipation: advances and clinical guidance",
abstract = "Currently opioids are the most frequently used medications for chronic noncancer pain. Opioid-induced constipation is the most common adverse effect associated with prolonged use of opioids, having a major impact on quality of life. There is an increasing need to treat opioid-induced constipation. With the recent approval of medications for the treatment of opioid-induced constipation, there are several therapeutic approaches. This review addresses the clinical presentation and diagnosis of opioid-induced constipation, barriers to its diagnosis, effects of opioids in the gastrointestinal tract, differential tolerance to opiates in different gastrointestinal organs, medications approved and in development for the treatment of opioid-induced constipation, and a proposed clinical management algorithm for treating opioid-induced constipation in patients with noncancer pain.",
keywords = "lubiprostone, methylnaltrexone, naloxegol, noncancer pain, peripheral µ opioid receptor antagonist, tolerance",
author = "Nelson, {Alfred D.} and Michael Camilleri",
year = "2016",
month = "3",
day = "1",
doi = "10.1177/2040622315627801",
language = "English (US)",
volume = "7",
pages = "121--134",
journal = "Therapeutic Advances in Chronic Disease",
issn = "2040-6223",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Opioid-induced constipation

T2 - advances and clinical guidance

AU - Nelson, Alfred D.

AU - Camilleri, Michael

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Currently opioids are the most frequently used medications for chronic noncancer pain. Opioid-induced constipation is the most common adverse effect associated with prolonged use of opioids, having a major impact on quality of life. There is an increasing need to treat opioid-induced constipation. With the recent approval of medications for the treatment of opioid-induced constipation, there are several therapeutic approaches. This review addresses the clinical presentation and diagnosis of opioid-induced constipation, barriers to its diagnosis, effects of opioids in the gastrointestinal tract, differential tolerance to opiates in different gastrointestinal organs, medications approved and in development for the treatment of opioid-induced constipation, and a proposed clinical management algorithm for treating opioid-induced constipation in patients with noncancer pain.

AB - Currently opioids are the most frequently used medications for chronic noncancer pain. Opioid-induced constipation is the most common adverse effect associated with prolonged use of opioids, having a major impact on quality of life. There is an increasing need to treat opioid-induced constipation. With the recent approval of medications for the treatment of opioid-induced constipation, there are several therapeutic approaches. This review addresses the clinical presentation and diagnosis of opioid-induced constipation, barriers to its diagnosis, effects of opioids in the gastrointestinal tract, differential tolerance to opiates in different gastrointestinal organs, medications approved and in development for the treatment of opioid-induced constipation, and a proposed clinical management algorithm for treating opioid-induced constipation in patients with noncancer pain.

KW - lubiprostone

KW - methylnaltrexone

KW - naloxegol

KW - noncancer pain

KW - peripheral µ opioid receptor antagonist

KW - tolerance

UR - http://www.scopus.com/inward/record.url?scp=84959360356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959360356&partnerID=8YFLogxK

U2 - 10.1177/2040622315627801

DO - 10.1177/2040622315627801

M3 - Article

AN - SCOPUS:84959360356

VL - 7

SP - 121

EP - 134

JO - Therapeutic Advances in Chronic Disease

JF - Therapeutic Advances in Chronic Disease

SN - 2040-6223

IS - 2

ER -